Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids with kidney disease: can dupilumab stop relapses?

NCT ID NCT07091175

Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if dupilumab, a drug already used for allergies, can help children with severe nephrotic syndrome stay relapse-free longer. About 66 kids aged 6–18 will get either dupilumab or a placebo injection for 6 months, while slowly reducing their steroid dose. The goal is to see if dupilumab can control the disease and reduce the need for steroids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 6 years old and 18 years old at the point of recruitment with idiopathic nephrotic syndrome with disease onset between 1-18 years old 2. Steroid-dependent disease or frequently relapsing disease prior to commencement of maintenance immunosuppression 3. On oral prednisolone +/- mycophenolate or levamisole only as maintenance therapy for 6 months or more, and with inadequate disease control or steroid toxicity on therapy 4. Nephrotic relapse or partial relapse (clinical or biochemical) within the last 1 year either unprovoked or during prednisolone wean, and which responded to increase in steroids 5. In complete remission at the time of recruitment 6. Competent with, and compliant to, daily urine protein monitoring with Albustix Exclusion Criteria: 1. Pre-existing ophthalmological conditions except refractive errors, squint or mild cataract 2. Current symptoms of helminth infection or travel to endemic areas, unless helminth infection is excluded 3. eGFR (by Bedside Schwartz equation) \<60 ml/min/1.73m2 4. Received Rituximab or other B-cell depleting agents within the last 1 year 5. Biopsy proven focal segmental glomerulosclerosis 6. Known ongoing infection including HIV, Hepatitis B, Hepatitis C or tuberculosis, otherwise immunosuppressed or with frequent infections 7. Known or suspected non-compliance to medication or follow-up 8. Pregnancy or intention to become pregnant 9. Major systemic conditions, i.e. ASA Physical Status III-IV. 10. Known hypersensitivity to dupilumab or any of its excipients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nephrotic syndrome in children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic steroid-sensitive nephrotic syndrome nephrotic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrotic syndrome in children Nephrotic syndrome steroid-dependent

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • KK Women's and Children's Hospital

    RECRUITING

    Singapore, Singapore, 229899, Singapore

  • National University Hospital

    RECRUITING

    Singapore, Singapore, 119228, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.